期刊文献+

塞来昔布对膀胱癌细胞T24增殖的影响 被引量:3

Effect of Celecoxib on proliferation of bladder cancer T24 cell
下载PDF
导出
摘要 目的观察塞来昔布对人膀胱癌细胞T24增殖的影响,并探讨其可能的作用机制。方法不同浓度塞来昔布(25、50、100和200μmoL·L-1)分别作用于人膀胱癌细胞T24不同时间(24h、48h和72h),MTT检测T24细胞增殖抑制率,半定量RT-PCR和Western-blot检测T24细胞中COX-2表达的变化。结果塞来昔布对膀胱癌T24细胞抑制作用存在剂量、时间依赖性,200μmoL·L-1塞来昔布作用72h时抑制率达75.7±1.9%,明显高于其它各组(P<0.05或0.01);半定量RT-PCR和Western-blot方法显示塞来昔布可显著降低T24细胞中COX-2mRNA和蛋白水平(P<0.05),且呈时间依赖性。结论塞来昔布可通过减少COX-2的表达抑制人膀胱癌细胞T24的增殖,并呈时间和剂量依赖性。 Objective To investigate the inhibitory effect of celecoxib on the growth of human bladder cancer cell T24 and its possible mechanism.Method The human bladder cancer cells T24 were treated respectively with 25,50,100 and 200μmoL·L^-1 celecoxib for 24,48 and 72 h.The inhibitory rate was detected by MTT assay,COX-2 mRNA levels by semiquantitative RT-PCR,and COX-2 protein levels by Western-blot.Results Celecoxib inhibited the proliferation of T24 in a time-dependent and dose-dependent manner.The inhibitory rate of 200μmoL·L^-1 celecoxib was 75.7±1.9% when treated for 72 hours,significantly higher than that in other groups (P〈0.01 or 0.05).Semiquantitative RT-PCR and Western blotting demonstrated that the levels of COX-2 expression decreased in a time-dependent manner in T24 bladder cancer cells after administration of celecoxib (P〈0.05).Conclusion Celecoxib inhibited the proliferation of human bladder cancer cell T24 in a dose-dependent and time-dependent manner by decreasing the expression of COX-2.
出处 《肿瘤药学》 CAS 2011年第4期379-381,共3页 Anti-Tumor Pharmacy
关键词 塞来昔布 人膀胱癌细胞 环氧化酶-2 凋亡 Celecoxib Human Bladder Cancer Cell COX-2 Apoptosis
  • 相关文献

参考文献9

  • 1李新武,黄叶容,朱建伟.卡培他滨联合奥沙利铂膀胱灌注对膀胱癌术后复发的影响[J].肿瘤药学,2011,1(3):203-205. 被引量:5
  • 2蒋莉,蒋艳.塞来昔布对肺癌的抑制作用机制研究[J].肿瘤药学,2011,1(3):216-219. 被引量:12
  • 3Edgar Ross.Update on the management of pain in arthritis and the use of cyclooxygenase-2 inhibitors[J]. Current Pain and Headache Reports . 2009 (6)
  • 4Tanaka MF,Sonpavde G.Diagnosis and management of urothelial carcinoma of the bladder. Postgraduate Medicine . 2011
  • 5Rizzo MT.Cyclooxygenase-2in oncogenesis. Clinica Chimica Acta . 2011
  • 6Li W,Wang J,Jiang HRet al.Combined effects of cyclooxy-genase-1and cyclooxygenase-2selective inhibitors on ovar-ian carcinoma in vivo. Int J Mol Sci . 2011
  • 7Suganuma M,Saha A,Fujiki H.New cancer treatment strat-egy using combination of green tea catechins and anticancer drugs. Cancer Science . 2011
  • 8Ghosh N,,Chaki R,Mandal V,et al.COX-2 as a target for cancerchemotherapy. Pharmacol Rep . 2010
  • 9Sakamoto C,Soen S.Efficacy and safety of the selective cyclooxygenase-2inhibitor celecoxib in the treatment of rheumatoid arthritis and osteoarthri-tis in Japan〔J〕. Digestion . 2011

二级参考文献16

  • 1马新成,魏长凤,岳建华.卡培他滨[J].齐鲁药事,2005,24(10):638-638. 被引量:13
  • 2许子亮,韩中朝.VEGF与血液学恶性疾病[J].国际病理科学与临床杂志,2006,26(4):318-320. 被引量:8
  • 3王艳,白淑平,王晓红.非小细胞肺癌组织中VEGF与P53蛋白表达及意义[J].现代生物医学进展,2007,7(11):1684-1686. 被引量:9
  • 4Cueni LN,Detmar M.New Insights into the Molecular Control of the Lymphatic Vascular System and its Role in Disease. The Journal of Investing . 2006
  • 5Achen MG,Mann GB,Stacker SA.Targeting lymphangiogen-esis to prevent tumour metastasis. British Journal of Cancer . 2006
  • 6de Gramont A,Figer A,Seymour M,et al.Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. Journal of Clinical Oncology . 2000
  • 7Su JL,,Yen CJ,Chen PS, et al.The role of the VEGF-C/VEGFR-3 axis in cancer progression. British Journal of Cancer . 2007
  • 8Miyata Y,Kanda S,Ohba K,et al.Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clinical Cancer Research . 2006
  • 9Bando H,Weich HA,Horiguchi S,et al.The association between vascular endothelial growth factor-C, its corresponding receptor, VEGFR-3, and prognosis in primary breast cancer: a study with 193 cases. Oncology Reports . 2006
  • 10Wolff H,Saukkonen K,Anttila S,et al.Expression of cyclooxygenase-2 in human lung carcinoma. Cancer Research . 1998

共引文献15

同被引文献20

  • 1杨名添,连臻强.乳腺癌内分泌治疗的进展[J].癌症,2007,26(4):440-444. 被引量:13
  • 2Jordan VC,O'Malley BW. Selective estrogen-receptor modulators and antihormonal resistance in breast cancer[J].{H}Journal of Clinical Oncology,2007,(36):5815-5824.
  • 3Suganuma M,Saha A,Fujiki H. New cancer treatment strategy using combination of green tea catechins and anti-cancer drugs[J].{H}CANCER SCIENCE,2011,(02):317-323.
  • 4Sakamoto C,Soen S. Efficacy and safety of the selective cyclooxygenase-2 inhibitor Celecoxib in the treatment of rheumatoid arthritis and osteoarthritis in Japan[J].Digest,2011,(01):108-123.
  • 5Rizzo MT. Cyclooxygenase-2 in oncogenesis[J].{H}Clinica Chimica Acta,2011,(9-10):671-687.
  • 6Hu M,Peluffo G,Chen H. Role of COX-2 in epi-thelial stromal cell interactions and progression of ductal carcinoma in situ of the breast[J].{H}Proceedings of the National Academy of Sciences(USA),2009,(09):3372-3377.
  • 7Falandry C,Canney PA,Freyer G. Role of com-bination therapy with aromatase and cyclooxygenase-2 inhibitors in patients with metastatic breast cancer[J].{H}ANNALS OF ONCOLOGY,2009,(04):615-620.
  • 8Baumann KH,Klusmeier E,Eggemann I. Effecrs of Celecoxib and Ly117018 combination on human breast cancer cells in vitro[J].Breast Cancer:Basic Clin Res,2009.23-24.
  • 9赵永庆,张富喜,曹巍子.乳腺癌COX-2表达及其与ER、PR、C-erbB-2的相关性[J].医学信息(手术学分册),2008,21(7):629-632. 被引量:2
  • 10刘锦,李贵新.COX-2与乳腺癌的发生发展[J].国际病理科学与临床杂志,2008,28(5):425-428. 被引量:2

引证文献3

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部